Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multiple dose, double blind, double-dummy, two-week 3 way cross-over, placebo-controlled clinical trial to assess the efficacy and safety of twice daily inhaled Aclidinium-bromide 400 µg compared to placebo and to an active comparator in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD)

Next Previous
Trial Profile

A multiple dose, double blind, double-dummy, two-week 3 way cross-over, placebo-controlled clinical trial to assess the efficacy and safety of twice daily inhaled Aclidinium-bromide 400 µg compared to placebo and to an active comparator in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Nov 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aclidinium bromide (Primary) ; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Almirall S.A.

Most Recent Events

  • 21 Apr 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2008-006886-10).
  • 08 Sep 2011 Results published in the Chest.
  • 22 Sep 2010 Results were presented at the 20th Annual Congress of the European Respiratory Society.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top